NCT06830629 MZE-829 APOL1-Mediated Kidney Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT06830629—A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT06830629 is a hot trial to watch
APOL1-Mediated Kidney Disease is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT06830629 is notable because it tests MZE-829 in a Phase 2 design with Safety and tolerability as assessed by incidence of adverse events (AEs) as a primary decision variable. The wider PatSnap topic query returned 6 trial records and 2 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT06830629 |
| Official title | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease |
| Phase / status | Phase 2 / Recruiting |
| Intervention | MZE-829 |
| Sponsor | Maze Therapeutics, Inc. |
| Geography | United States, United Kingdom, France |
| Enrollment | 56 |
| Primary endpoint | Safety and tolerability as assessed by incidence of adverse events (AEs) |
| Endpoint time frame | Day 1 to Week 12 |
| Primary completion | 2026-09-01 |
| Study completion | 2026-09-01 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Safety and tolerability as assessed by incidence of adverse events (AEs)—determines what uncertainty this study can resolve. The reported time frame is Day 1 to Week 12. Enrollment of 56 participants and geography in United States, United Kingdom, France shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- #1770 AMPLITUDE, a Ph2/3 adaptive trial of inaxaplin in APOL1-mediated kidney disease (Phase 2/3): Age = 42.7 year .
- Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD) (Phase 1): T1/2 = - 15 hours .
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: MZE-829 (Phase 2; APOL1).
Company & Deal Intelligence context: Maze Therapeutics, Inc. (MAZE) — http://www.mazetx.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT06830629 is a focused lens on APOL1-Mediated Kidney Disease development. Its value will be determined by whether MZE-829 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
